RxSight, Inc. (RXST) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.87
↓-79% vs avg
5yr avg: 4.22
30Y Low1.6·High8.7
ROE
↑
-14.0%
↓+56% vs avg
5yr avg: -31.8%
30Y Low-59%·High-12%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RXST Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
RxSight, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $239M | $429M | $1.3B | $1.4B | $350M | $308M | — | — |
| Enterprise Value | $230M | $420M | $1.3B | $1.4B | $384M | $328M | — | — |
| P/E Ratio → | -6.11 | — | — | — | — | — | — | — |
| P/S Ratio | 1.78 | 3.19 | 9.55 | 15.60 | 7.15 | 13.63 | — | — |
| P/B Ratio | 0.87 | 1.56 | 4.75 | 8.66 | 3.90 | 2.23 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
RXST EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.12 | 9.52 | 15.52 | 7.83 | 14.54 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
RXST Profitability
Margins and return-on-capital ratios measuring operating efficiency
RxSight, Inc. earns an operating margin of -35.8%. Operating margins have expanded from -56.2% to -35.8% over the past 3 years, signaling improving operational efficiency. A negative ROE of -14.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 76.6% | 76.6% | 70.7% | 60.4% | 43.5% | 20.0% | 11.6% | -81.2% |
| Operating Margin | -35.8% | -35.8% | -26.3% | -56.2% | -129.2% | -233.6% | -241.2% | -2055.8% |
| Net Profit Margin | -29.0% | -29.0% | -19.6% | -54.6% | -136.2% | -215.5% | 187.9% | 5632.3% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -14.0% | -14.0% | -12.4% | -38.8% | -58.5% | -35.2% | — | — |
| ROA | -12.4% | -12.4% | -11.0% | -29.2% | -38.9% | -33.2% | 26.1% | 114.3% |
| ROIC | -13.3% | -13.3% | -12.8% | -27.1% | -33.7% | -24.9% | — | — |
| ROCE | -16.7% | -16.7% | -16.2% | -34.0% | -40.3% | -39.0% | -37.1% | -45.2% |
RXST Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $20M exceeds total debt of $11M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.04 | 0.02 | 0.50 | 0.33 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.03 | -0.02 | -0.04 | 0.37 | 0.15 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -970.90 | -970.90 | -1304.00 | -13.69 | -12.50 | -12.22 | 55.18 | 4856.54 |
Net cash position: cash ($20M) exceeds total debt ($11M)
RXST Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
RxSight, Inc.'s current ratio of 10.95x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 9.75x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 8.06x to 10.95x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.95 | 10.95 | 11.36 | 8.06 | 7.81 | 15.92 | 7.03 | 10.67 |
| Quick Ratio | 9.75 | 9.75 | 10.50 | 7.22 | 6.95 | 15.19 | 6.31 | 9.81 |
| Cash Ratio | 8.69 | 8.69 | 9.17 | 6.08 | 6.14 | 14.38 | 5.95 | 9.54 |
| Asset Turnover | — | 0.43 | 0.44 | 0.49 | 0.33 | 0.12 | 0.15 | 0.02 |
| Inventory Turnover | 1.00 | 1.00 | 1.86 | 2.03 | 1.87 | 2.25 | 1.57 | 0.56 |
| Days Sales Outstanding | — | 63.47 | 78.39 | 83.10 | 81.60 | 78.55 | 71.24 | 128.51 |
RXST Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
RxSight, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $41M | $39M | $34M | $28M | $27M | $19M | $19M |
Peer Comparison
Compare RXST with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RXSTYou | $239M | -6.1 | — | — | 76.6% | -35.8% | -14.0% | -13.3% | — |
 LMAT | $2B | 42.8 | 33.4 | 33.0 | 71.5% | 27.2% | 15.8% | 9.7% | 2.4 |
 ATRC | $1B | -115.8 | 77.7 | 29.2 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 |
 IRTC | $4B | -89.8 | — | 118.8 | 70.6% | -4.9% | -36.6% | -5.2% | — |
 TMDX | $3B | 15.0 | 18.4 | 18.9 | 59.9% | 17.9% | 54.2% | 18.8% | 3.5 |
 ALGN | $12B | 29.8 | 13.9 | 24.6 | 68.3% | 15.3% | 10.4% | 15.4% | 0.1 |
 AHCO | $2B | -22.6 | 5.7 | 7.3 | 17.5% | 5.7% | -4.6% | 4.0% | 3.2 |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ABT | $151B | 11.4 | 15.8 | 23.8 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
 BSX | $84B | 29.2 | 25.3 | 23.0 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 MDT | $100B | 21.6 | 14.3 | 19.3 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See RXST's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RXST Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RXST vs LMAT
Side-by-side business, growth, and profitability comparison vs LeMaitre Vascular, Inc..
Start ComparisonRXST — Frequently Asked Questions
Quick answers to the most common questions about buying RXST stock.
What is RxSight, Inc.'s P/E ratio?
RxSight, Inc.'s current P/E ratio is -6.1x. This places it at the 50th percentile of its historical range.
What is RxSight, Inc.'s ROE?
RxSight, Inc.'s return on equity (ROE) is -14.0%. The historical average is -31.8%.
Is RXST stock overvalued?
Based on historical data, RxSight, Inc. is trading at a P/E of -6.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are RxSight, Inc.'s profit margins?
RxSight, Inc. has 76.6% gross margin and -35.8% operating margin.